Overview

Keytruda is the brand name for pembrolizumab, a humanized monoclonal antibody developed as an immuno-oncology medicine by Merck & Co. Rather than directly attacking tumor cells in the manner of traditional cytotoxic chemotherapy, pembrolizumab acts on an immune-regulatory pathway. It binds to the programmed cell death protein 1, or PD-1, receptor on immune cells and blocks interaction with its ligands PD-L1 and PD-L2. In suitable patients, this can restore or strengthen T-cell activity against malignant cells. Treatment selection may depend on tumor type, disease stage, biomarker results such as PD-L1 expression, microsatellite instability or mismatch-repair status, and the applicable regulatory label. The scientific work that ultimately led to Keytruda began at Organon in the Netherlands in the early 2000s. After Merck acquired Schering-Plough in 2009, the program became part of Merck’s pipeline. Merck accelerated clinical development and pursued a regulatory strategy centered on immunotherapy’s potential across multiple tumor types. In 2014, the U.S. Food and Drug Administration granted an initial approval for advanced melanoma, making pembrolizumab one of the early commercial examples of PD-1 checkpoint blockade. Subsequent approvals expanded the medicine into additional melanoma settings and a wide range of solid tumors, including non-small-cell lung cancer, head and neck cancer, urothelial cancer, renal cell carcinoma, cervical cancer, gastric and esophageal cancers, and certain biomarker-defined cancers. Some indications are monotherapy uses, while others combine Keytruda with chemotherapy, radiotherapy, targeted medicines or other immunotherapies. Keytruda’s clinical and commercial importance has been driven by the breadth of its development program. Merck tested the drug in different lines of therapy, disease stages and biomarker-defined populations, including studies that established a role in first-line treatment for selected patients with advanced non-small-cell lung cancer. The brand’s growth also reflects a strategic shift in oncology marketing. Merck initially concentrated heavily on professional and medical-journal communication, but later introduced direct-to-consumer advertising that used patient narratives, biomarker education and explanations of treatment decisions. The “It’s Tru” campaign featured real patients, and later executions included an oncologist speaking about treatment alongside a patient. More recent “Known For” and “Keytruda Moment” materials frame people through their relationships, activities and aspirations while presenting the medicine as one option within physician-directed cancer care. Keytruda is administered by intravenous infusion in its conventional formulation. Merck has also pursued formulation and delivery innovations, including Keytruda QLEX, a combination of pembrolizumab and berahyaluronidase alfa-pmph intended to support subcutaneous administration where approved. Because checkpoint inhibition activates immune responses, the product carries important risks of immune-mediated adverse reactions affecting organs such as the lungs, colon, liver, kidneys, endocrine glands, skin and nervous system. Prescribing information, indication-specific evidence and local regulatory requirements therefore govern its use. The brand is a central asset in Merck’s oncology portfolio and has faced intense competition from other checkpoint inhibitors, particularly Bristol Myers Squibb’s Opdivo. Its future is also shaped by patent and exclusivity considerations, pricing and access debates, regulatory review, and Merck’s effort to develop or acquire successor oncology products and combination therapies. Keytruda remains an active global pharmaceutical brand, but its exact approved uses, formulation availability and reimbursement conditions differ by jurisdiction.

History

Keytruda’s origins lie in an antibody research program begun at Organon in the Netherlands in 2003. Scientists including Andrea van Elsas, Hans van Eenennaam and John Dulos worked on using antibody technology to influence immune regulation. The program focused on PD-1, an immune checkpoint that can be exploited by tumors to suppress T-cell activity. The resulting molecule was later known as pembrolizumab. Merck obtained the program through its 2009 acquisition of Schering-Plough, which had inherited Organon’s relevant assets. The company made pembrolizumab a priority in oncology and organized a rapid clinical and regulatory development strategy. Early trials in advanced melanoma produced responses in patients whose disease had progressed after other treatments. In September 2014, the FDA authorized Keytruda for advanced melanoma under an accelerated pathway. This approval placed Merck among the first pharmaceutical companies to commercialize a PD-1 inhibitor and gave the company a foundation for a much larger oncology franchise. Merck subsequently tested Keytruda across tumor types, stages of disease and lines of therapy. The development program explored both biomarker-selected and broader patient populations. In lung cancer, studies examined PD-L1 expression and helped establish Keytruda’s role in selected first-line and later-line non-small-cell lung cancer settings. Other programs supported approvals or label expansions in head and neck cancer, urothelial carcinoma, renal cell carcinoma, classical Hodgkin lymphoma, melanoma, cervical cancer, endometrial cancer, gastric and gastroesophageal cancers, esophageal cancer, triple-negative breast cancer and several tissue-agnostic biomarker-defined indications. The exact label has changed over time and varies between jurisdictions. A major strategic feature of Keytruda’s history has been combination development. Merck evaluated the drug with chemotherapy and with other anticancer agents, seeking to improve outcomes in diseases where immune activation alone was insufficient. The product’s clinical role consequently expanded from a treatment for a relatively narrow group of advanced melanoma patients to a platform-like medicine used in numerous oncology treatment pathways. Its success also made checkpoint inhibition a central competitive field, with Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq and other immunotherapies competing for indications, prescribers and payer access. Marketing evolved alongside the clinical expansion. Merck initially relied more heavily on professional communications and medical-journal advertising than on mass-market television. From 2017, the company increased direct-to-consumer activity in lung cancer, including the “It’s Tru” campaign. The campaign used patient stories and discussed the relevance of PD-L1 testing. A later advertisement featured a real patient, while 2019 executions added practicing oncologist Goetz Kloecker to the format. Subsequent creative work, including “Keytruda Moment” and “Known For,” used broader multi-indication and human-interest narratives. These campaigns were part of a wider effort to explain immunotherapy to patients and caregivers while remaining subject to prescription-drug risk disclosures. Merck has continued to extend the brand through additional indications, combinations and delivery technologies. Keytruda QLEX combines pembrolizumab with berahyaluronidase alfa-pmph and represents an effort to provide a subcutaneous option where regulators authorize it. The formulation is linked to Merck’s broader strategy of protecting the franchise through innovation and lifecycle management. The brand’s later history has also been defined by commercial concentration and future exclusivity pressure. Keytruda became Merck’s leading product and a major driver of the company’s oncology business. Analysts and industry observers have focused on the expected loss of important patent protection later in the decade, prompting Merck to pursue new oncology assets, combinations and acquisitions that could offset the eventual decline. These corporate strategies concern the parent company rather than a change in Keytruda’s identity: Keytruda remains an active pembrolizumab brand with a broad global regulatory and clinical footprint.

2019
Real oncologist appears in “It’s Tru” advertisements
[4]Merck adds real doctor to Keytruda patient advertisementsfiercepharma.com
Merck adds oncologist Goetz Kloecker to patient-oriented Keytruda television spots.
2017
First major television advertising push
[7]First major television advertising pushfiercepharma.com
Merck begins national television advertising focused on Keytruda’s first-line NSCLC positioning and biomarker testing.
2014
Initial U.S. approval for advanced melanoma
[1]KEYTRUDA and KEYTRUDA QLEX official websitekeytruda.com
The FDA authorizes Keytruda for advanced melanoma, establishing its commercial presence in immuno-oncology.
2009
Merck gains the program through Schering-Plough acquisition
[6]The history behind Merck’s cancer immunotherapyforbes.com
Merck’s acquisition of Schering-Plough brings the developing pembrolizumab program into Merck’s pipeline.
2003
Research program begins at Organon
[5]Dutch scientists associated with Keytruda’s originslabiotech.eu
Dutch scientists at Organon begin work on the antibody program that would ultimately produce pembrolizumab.

Products and positioning

A broad-spectrum, physician-directed immuno-oncology brand positioned around PD-1 checkpoint inhibition, biomarker-informed treatment and use across multiple cancer types.

Prescription oncology immunotherapy · 2014
Keytruda
The primary pembrolizumab product, a PD-1-blocking monoclonal antibody administered by intravenous infusion. Its approved uses cover multiple cancers and biomarker-defined settings, with monotherapy and combination regimens depending on the label and jurisdiction. Immune-mediated adverse reactions are a defining safety consideration.
Subcutaneous oncology formulation
Keytruda QLEX
A formulation combining pembrolizumab with berahyaluronidase alfa-pmph. It is intended to enable subcutaneous delivery where approved, representing a lifecycle and administration innovation for the Keytruda franchise.

Marketing campaigns

2023Known For
United States
Television executions portrayed people through personal qualities, family roles, interests and aspirations while presenting Keytruda in a cancer-treatment context.
Outcome. The campaign continued Merck’s human-interest approach to prescription oncology advertising.
Source
2021The Keytruda Moment
United States
A multi-indication direct-to-consumer platform connected the moment of diagnosis with the possibility of Keytruda across numerous advanced cancers rather than focusing on one disease alone.
Outcome. The work broadened the brand’s consumer messaging across its expanding oncology indications.
Source
2019It’s Tru: real doctor and patient
United States
Two spots featured practicing oncologist Goetz Kloecker, including an advertisement in which he appeared with patient Katy. The creative emphasized physician-patient discussion and Kloecker’s clinical perspective.
Outcome. Merck said consumer feedback supported adding a real oncologist to the campaign format.
Source
2017It’s Tru
United States
Merck’s patient-centered campaign used television and digital storytelling to describe living with advanced cancer and the role of Keytruda. One later execution featured a real patient whose treatment history was connected to a PD-L1-selected NSCLC clinical program.
Outcome. The campaign expanded Keytruda’s direct-to-consumer presence and became a recognized example of real-patient pharmaceutical advertising.
Source

Brand decisions

2017
Shift toward national direct-to-consumer television advertisingStrategy
Background
Merck had initially emphasized professional and journal advertising, while rival Opdivo had already established a visible television presence.
Action taken
Merck launched national Keytruda television advertising centered first on lung cancer and patient stories.
Aftermath
Keytruda became part of a highly visible advertising contest in immuno-oncology, particularly against Opdivo.
- Bristol Myers Squibb — Bristol Myers Squibb continued promoting Opdivo through its own national advertising and competed directly for attention in immuno-oncology.
Source
Lifecycle development through an alternate delivery formulationStrategy
Background
Merck has sought to extend the Keytruda franchise through formulation and administration improvements as well as new indications.
Action taken
The company developed Keytruda QLEX, combining pembrolizumab with berahyaluronidase alfa-pmph for subcutaneous delivery where authorized.
Aftermath
The formulation’s availability and clinical use depend on regulatory approval in each market.
Source

Recent events

Unconfirmed
Reported2021.10.22
NOXXON and MSD collaborate on NOX-A12 study[10]NOXXON与MSD合作开展NOX-A12研究finanznachrichten.de
NOXXON and MSD entered a collaboration for MSD to provide pembrolizumab (Keytruda) and expert advice for the OPTIMUS study of NOX-A12 in second-line pancreatic cancer.
2021.08.12
Reported2021.08.12
FDA approves Keytruda and Lenvima combination for advanced kidney cancer[11]FDA 批准 Keytruda 与 Lenvima 联合治疗晚期肾癌pharmatimes.com
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
2021.08.06
Reported2021.08.06
BioInvent and MSD enter a clinical-trial collaboration for BI-1808 and KEYTRUDA[12]BioInvent与MSD达成BI-1808和KEYTRUDA临床试验合作prnewswire.com
BioInvent announced a second clinical-trial collaboration and supply agreement with MSD to evaluate BioInvent’s BI-1808 with MSD’s KEYTRUDA in a Phase 1/2a trial involving patients with lung and ovarian cancer.
2021.07.27
Reported2021.07.27
FDA approves KEYTRUDA for high-risk early-stage triple-negative breast cancer[13]FDA 批准 KEYTRUDA 用于高风险早期三阴性乳腺癌finanznachrichten.de
The U.S. Food and Drug Administration approved Merck's KEYTRUDA, in combination with chemotherapy before surgery and as a single agent after surgery, for patients with high-risk early-stage triple-negative breast cancer.
Unconfirmed
Reported2021.07.22
FDA approves Keytruda–Lenvima combination for advanced endometrial carcinoma[14]FDA批准Keytruda与Lenvima联合治疗晚期子宫内膜癌finanznachrichten.de
The U.S. Food and Drug Administration approved Keytruda in combination with Lenvima for certain patients with advanced endometrial carcinoma following prior systemic therapy who are not candidates for curative surgery or radiation.
2021.03.08
Reported2021.03.08
Dracen and Merck enter clinical trial and supply agreement for sirpiglenastat and KEYTRUDA[15]Dracen 与 Merck 就 sirpiglenastat 和 KEYTRUDA 达成临床试验及供应协议prweb.com
Dracen announced that it had entered into a clinical trial and supply agreement with Merck to evaluate sirpiglenastat in combination with KEYTRUDA in patients with solid tumors. The announced Phase 1b trial is expected to begin by the first quarter of 2022.
2020.10.29
Reported2020.10.29
Sanofi and MSD agree to test THOR-707 with Keytruda[16]赛诺菲与MSD同意测试THOR-707与Keytruda的联合疗法pharmatimes.com
Sanofi entered an agreement with MSD to collaborate on a phase II trial evaluating Sanofi's investigational candidate THOR-707 alongside MSD's Keytruda.
2020.08.12
Reported2020.08.13
QBiotics and MSD clinical collaboration[17]QBiotics与MSD开展临床合作prnewswire.com
QBiotics announced that it had entered into an agreement with MSD to evaluate tigilanol tiglate in combination with Keytruda in patients with unresectable melanoma.
2020.06.17
Reported2020.06.17
FDA approves a new KEYTRUDA indication[18]FDA批准KEYTRUDA新适应症finanznachrichten.de
The FDA approved KEYTRUDA monotherapy for certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors after prior treatment when no satisfactory alternative treatment options are available. The indication was approved under accelerated approval.
2020.06.17
Reported2020.06.17
FDA approves FoundationOne CDx as a KEYTRUDA companion diagnostic[18]FDA批准KEYTRUDA新适应症finanznachrichten.de
The FDA approved FoundationOne CDx as the companion diagnostic to identify patients with TMB-H solid tumors who may benefit from KEYTRUDA monotherapy.

Related entries

Merck KGaA